

Haworthia Duval – 74, *Gasteria Duval* – 23 таксона. Кроме этого в коллекции представлены межродовые гибриды – *xGasteraloe Guillaumin* (*Gasteria x Aloe*), *xGasterhaworthia Guillaumin* (*Gasteria x Haworthia*), *xAstroworthia G.D Rowley* (*Astroloba Uitewaal x Haworthia*). Большинство растений включены в международные красные списки. В процессе формирования этой части коллекции были проведены исследования морфологии цветов, соцветий и семян; проведены фенологические наблюдения за цветением и плодоношением; разработаны методы вегетативного и семенного размножения представителей семейства. Фенологические наблюдения показали, что основные сроки цветения характерны в весенне-летние месяцы, но для *Aloe* в условиях оранжерей характерны еще два пика цветения (август, декабрь). Показано, что кроме простой и сложной кисти у большинства видов, для *Aloe haworthioides* характерно соцветие колос; форма околоцветника трубчатая или цилиндрическая, что, вероятнее всего, выполняет защитную функцию. Цветение одного цветка проходит в три этапа, что предполагает эффект самоопыления, который подтвержден в условиях культуры для некоторых видов *Aloe*, а жизнеспособность пыльцы тесно связана с температурой окружающей среды. Свежесобранные семена, полученные в результате само- или перекрестного опыления имеют достаточно высокую всхожесть, которая увеличивается через три месяца. Предложен метод увеличения жизнеспособности семян растений семейства *Aloaceae* в 2,5-3 раза и разработан метод вегетативного размножения представителей родов *Haworthia* и *Gasteria* листовыми черенками.

Ключевые слова: семейство *Aloaceae*, соцветие, цветок, семя, вегетативное и семенное размножение.

M. Gaidarzhly, Dr. Sci.

O.V. Fomin Botanical Garden, Education and Science Center "Institute of Biology and Medicine",
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

REPRODUCTIVE BIOLOGY OF THE PLANTS OF THE ALOACEAE FAMILY IN THE GREENHOUSE

The article presents the results of the study of the reproductive biology of succulent plants of the *Aloaceae* family in the introduction. Representatives of the family are part of the collection of succulent plants of the O.V. Fomin Botanical Garden, which contains over 190 species, subspecies and hybrids of plants of three genera: *Aloe* Linne – 86, *Haworthia* Duval – 74, *Gasteria* Duval – 23 taxa. In addition, *xGasteraloe Guillaumin* (*Gasteria x Aloe*), *xGasterhaworthia Guillaumin* (*Gasteria x Haworthia*), *xAstroworthia G.D Rowley* (*Astroloba Uitewaal x Haworthia*). Most plant species are included in the international red lists. In the process of forming this part of the collection, the morphology of flowers, inflorescences and seeds was investigated, phenological observations of flowering and fruiting were conducted, methods of vegetative and seed reproduction of family members were developed. Phenological observations have shown that the main flowering period is the spring-summer period, but *Aloe* under greenhouse conditions is characterized by two more peaks (August, December). We have found that, in addition to simple or complex tics, in the vast majority of species, *Aloe haworthioides* is characterized by inflorescences of ears; perianth shaped tubular or cylindrical, inherent in the vast majority of species and performs, in our opinion, a protective function. The flowering of a single flower takes place in three stages, providing a self-pollination effect that is characteristic of crop conditions only for certain *Aloe* species, and the viability of the pollen is closely related to the ambient temperature. Freshly harvested seeds obtained by self-pollination or cross-pollination have a sufficiently large germination, but if stored in any way after three months, the germination increases. We have proposed a method of increasing the viability of seeds of plants of the *Aloaceae* family 2.5-3 times and developed a method of vegetative propagation of representatives of the genera *Haworthia* and *Gasteria* leaf cuttings.

Keywords: *Aloaceae* family, inflorescences, flower, seeds, seed and vegetative reproduction.

UDC616-006.48-039.

N. Senchylo, Ph. D.
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,
O. Gorbach, Ph. D.
National Cancer Institute, Kyiv, Ukraine,
L. Dubovtseva, stud.
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,
O. Skachkova, Ph. D.
National Cancer Institute, Kyiv, Ukraine,
P. Yakovlev, Ph. D.
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,
T. Skaterna, Ph. D.
Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine (NASU), Kyiv, Ukraine,
L. Drobot, Dr.Sci.
Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine (NASU), Kyiv, Ukraine,
L. Garmanchuk, Dr.Sci.
Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

TEICHOIC ACID DIFFERENTIALLY MODULATES TLR4 EXPRESSION IN SENSITIVE AND RESISTANT TO CISPLATIN SMALL CELL LUNG CARCINOMA H69 CELLS

The Toll-like receptor family plays crucial role in the innate immune system, recognizing the molecular structures associated with pathogens derived from different microbes. TLRs also recognize the molecular structures associated with damage associated with certain diseases, such as cancer. They can either promote tumorigenesis, or suppress it. Besides, the promotion of the tumor cells growth may be associated with the acquisition of drug resistance. The data on the TLR4 expression level changes during this pathological process are controversial. That is why the purpose of our study was to determine the expression level of TLR4 in cisplatin-sensitive and cisplatin-resistant lung cancer cells. Cells line NCI-H69 (human small cell lung carcinoma) and a drug resistant subline of NCI-H69/CPR were used to determine the expression level of TLR4. Incubation of cells with teichoic acid (1 µg / ml) was performed under standard conditions for two days. The level of TLR4 expression in the cell was determined with RT-PCR at 7500 Real-Time PCR Systems ("Applied Biosystems", USA) and specific primers and asymmetric cyan cationic fluorochrome SYBRGreen (C32H37N4S⁺) with spike of consumption at $\lambda_{max} = 488$ nm and fluorescence at $\lambda_{max} = 522$ nm. It was shown that TLR4 expression level was almost two times lower in WT H69 cells compared with H69 cells resistant to cisplatin. In contrast, teichoic acid oppositely influenced TLR4 expression level: increased by 1.3-times in WT H69 cells whereas decreased 4-times in H69 cells resistant to cisplatin compared with corresponding control samples without teichoic acid. In cisplatin-resistant lung cancer cells found high expression of TLR4 can be inhibited by adding teichoic acid ligand to TLRs.

Key words: TLR4 expression, NCI-H69 and NCI-H69/CPR cisplatin-resistant cells line, teichoic acid.

Introduction. The Toll-like receptor family (TLR) is a member of the interleukin-1 (IL-1R) / TLR receptor superfamily. This superfamily was described in 1998 as a family

of type I transmembrane proteins containing an intracellular TIR domain with common basic structure [1]. TLRs play crucial role in the innate immune system, recognizing the

molecular structures associated with pathogens derived from different microbes. TLRs also recognize the molecular structures associated with damage associated with certain diseases, such as cancer [2].

TLR activation was associated with both tumor suppression and tumor progression. Tumors are infiltrated by different types of immune cells, and immune cells can be the main cell population in the tumor microenvironment. Therefore, it is increasingly recognized that inflammatory processes play key role in tumorigenesis [3].

TLR ligands are often used as adjuncts to enhance immunogenicity of vaccines in anticancer therapy [4]. Such ligands are the cell wall biopolymers derived from gram-positive microorganisms *Staphylococcus aureus*, the teichoic acids (TA). Our previous studies have shown that TA in combination with the bimetallic copper and cadmium complex with ethylenediamine (PO244) exacerbated the antitumor activity of the latter. However, incubation of primary Lewis lung carcinoma cells with TA leads to an increase in aneuploidy cell population and a decrease in apoptotic cell levels. But in combination with PO244, TA provided 2-fold increase in the level of LLC apoptotic cells and reduced the population of LLC cells in the proliferative pool (G2 / M + S phase) to 40%, compared to 65% in control [5]. TLR4 expression is characteristic of innate immunity. However, the activation of TLR4 in the tumor process may be associated with tumor initiation and progression. Different types of tumors may have different patterns of TLR4 involvement during tumorigenesis or tumor progression [6]. In addition, in some tumor models, TLR2 and TLR4 polymorphisms are known to affect cancer risk, which means that a genetic difference in specific TLR may be associated with specific tumor behavior [7]. Cisplatin therapy is widely used anticancer treatment for various neoplasms. However, this compound causes side effects in healthy tissues and body systems, and causes drug resistance [8,9]. There is various evidence regarding the involvement of TLRs, in particular TLR4, in the emergence of cisplatin resistance.

Therefore, the purpose of our study was to determine the expression level of TLR4 in cisplatin-sensitive and cisplatin-resistant lung cancer cells

Materials and method. *Cells line* NCI-H69/CPR (human small cell lung carcinoma) is a drug resistant subline of NCI-H69 (Sigma Catalogue number. 91091802) were used to determine the expression level of TLR4. Drug resistance was developed by addition of cisplatin in a step-wise increment to the growth medium of the parental line. The cell line exhibits a 5-fold resistance to cisplatin and is cross resistant to melphalan. The cells were incubated in culture medium RPMI 1640+2mM glutamine + 0.4 µg/ml cisplatin + 10% fetal bovine serum (FBS). Incubation of cells with teichoic acid (1 µg/ml) derived from gram-positive microorganisms *Staphylococcus aureus* was performed under standard conditions for two days.

Total RNA was isolated by phenol-chloroform extraction and the "Ribo-zol" kit ("AmpliSens"). RNA concentration in all samples was measured by Thermo Scientific Nano Drop-1000 (Thermo Fisher Scientific, USA) and samples were diluted to 200 ng/µl. cDNA was obtained from total RNA by RT-PCR using "High Capacity cDNA Reverse Transcription Kit" (Applied Biosystems, USA). The reverse transcription reaction was run under the following conditions: 25 °C – 10 min, 37 °C – 120 min and 85 °C – 5 sec. cDNA was diluted in half with DNA buffer. TLR4 expression level was evaluated by real-time PCR on 7500 Real-Time PCR Systems ("Applied Biosystems", USA) using specific primers and fluorochrome SYBR Green ("Applied Biosystems", USA). GAPDH was used to normalize levels of mRNA for the relative quantification method of analysis. TLR4 sequence (f- CTGTGTCAGTCACGGAGCC, r- GCAGGTAGTGGGAGAAGCC) and GAPDH sequence (f- GCCAAGGTCATCCATGACAACCTTTGG, r- GCCTGCTTCACCACCTTCTTGATGTC) were constructed by Primer Express® Software v3.0 (Applied Biosystems, USA). 45 cycles real-time PCR (94 °C – 15 sec, 65 °C – 15 sec and 72 °C – 30 sec) were run on 7300/7500 Real-Time PCR Systems, "Applied Biosystems", USA. Calculations were performed using the $\Delta\Delta C_t$ relative quantification method.

Results. Lung cancer cells sensitive (NCI-H69) and resistant to cisplatin (NCI-H69/CPR) differ in a number of morph functional characteristics, especially proliferative and adhesive properties (Fig. 1).





Fig. 1. Morphological features of WT (NCI-H69) and resistant to cisplatin (NCI-H69/CPR) small cell lung carcinoma NCI-H69 cells. Cells were imaged under phase-contrast microscopy

Incubation of NCI-H69 and NCI-H69/CPR cells was carried out for one and two days without and with TA at a concentration of 1 µg / ml. Through after day of cultivation,

it was found that in the wild type cells, the expression level of TLR4 was 0.002613 ± 0.000432 a.u., whereas on the second day of incubation this indicator increased slightly

and was 0.002814 ± 0.000202 a.u. With respect to the cisplatin-resistant cell line, almost twice the expression level of TLR4 was detected compared to the WT cells and this

indicator did not change on the second day of incubation of cells under standard conditions (Fig. 2).



Fig/ 2. TLR4 expression level in NCI-H69 and NCI-H69 / CPR cells under standard incubation conditions

*-P<0.05 vs control (WT NCI-H69 cells)

Since no differences in the expression of TLRs at 1 and 2 days of incubation were detected, the expression of TLR4 under the action of TA was determined after 2 days of incubation. Preincubation of cells of both lines for two

days with TA led to the following results: in WT cells it was possible to observe the increase of expression of TLR4 gene, whereas in the cisplatin-resistant cells we revealed a pronounced inhibitory effect of the TLR ligand (Fig. 3).




Fig. 3. TLR4 expression level in NCI-H69 and NCI-H69 / CPR cells by adding TA

*-P<0.05 vs WT NCI-H69, ^-P<0.05 vs cells without TA

Thus, It was shown that the TLR 4 expression level was almost twice lower in the WT cells than in the cisplatin-resistant cells. The effect of teichoic acid resulted in an increase of TLR4 expression in the WT cells line strain 1.3-times compared to control, whereas in cisplatin-resistant cells TLR4 expression level decreased 4-times compared to the sample without the effect of teichoic acid. The research conducted by Lewison carcinogenic lung indicates a significant role of TLR4 not only in tumor growth but also

in migration [10]. The refore, inhibition of expression of the sereceptors may be considered as a new strategy for antitumor and time tastaction. It is also possible to use inhibition of the expression of TLR by specific ligands in combination with antitumor agents in resistant tumors.

Conclusion. Thus, in cisplatin-resistant lung cancer cells found high expression of TLR4 can be inhibited by adding a ligand to TLRs.

Список використаних джерел:

1. Akira S. Toll-Like Receptor Signaling / S. Akira and K. Takeda // *Nature Reviews Immunology*, 4, 499–511. (2004) <https://doi.org/10.1038/nri1391>
2. Masahiro Y. Current Views of Toll-Like Receptor Signaling Pathways / Y. Masahiro, T. Kiyoshi // *Gastroenterology Research and Practice*, vol. 2010, Article ID 240365, 8 pages, 2010. <https://doi.org/10.1155/2010/240365>
3. Braunstein, M. <https://doi.org/10.1007/s11523-018-0589-7> Eui Young So, Toru Ouchi The application of Toll like receptors for cancer therapy / M. Braunstein, J. Kucharczyk, S. Adams // *Int J BiolSci* 2010; 6(7):675–681. (2018) doi:10.7150/ijbs.6.675
4. Combined influence of teichoic acids from *Staphylococcus aureus* and heterometallic Cu/Cd ethylenediamine complex on peritoneal macrophages and tumor cells. / V.V. Nikulina, L.V. Garmanchuk, N.V. Senchylo et al. // *Cytology and Genetics*, 2014. – Vol. 48, Is. 6. – P. 392–397.
5. The Anticancer Effect of Teichoic Acids on Lewis Lung Carcinoma Model / V. Nikulina, L. Garmanchuk, T. Nikolaienko, N. Senchylo // *J. of Thoracic Oncology*, 2016. – Vol. 12, No. 1S. – S843–S844.
6. Mai C. W. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers / Mai Chun Wai et al. // *OncoTargets and therapy*, 2013. – 6. – P. 1573–1587. doi: 10.2147/OTT.S50838.
7. de Oliveira J. G. Polymorphisms of the TLR2 and TLR4 genes are associated with risk of gastric cancer in a Brazilian population / J.G. de Oliveira, A.E. Silva // *World Journal of Gastroenterology*, 2012. – 18(11). – P. 1235–1242. doi: 10.3748/wjg.v18.i11.1235.
8. Cancer drug resistance: An evolving paradigm / C. Holohan, S. van Schaeybroeck, D.B. Longley, P.G. Johnston // *Nat. Rev.*, 2013. – 13. – P. 714–726. doi: 10.1038/nrc3599.
9. Drug Resistance in Cancer: An Overview / G. Housman, S. Byler, S. Heerboth, et al. // *Cancers (Basel)*, 2014. – 6(3). – P. 1769–1792.
10. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-1 and IL-10 and tumor cells migration / Chun Lia, Haixia Lib, Kun Jianga et al. // *Bio-Medical Materials and Engineering*, 2014. – 24. – P. 869–875.
3. Braunstein, M.J., Kucharczyk, J. & Adams, S. *TargOncol* (2018) 13: 583. <https://doi.org/10.1007/s11523-018-0589-7> Eui Young So, Toru Ouchi The application of Toll like receptors for cancer therapy *Int J BiolSci* 2010; 6(7):675–681. doi:10.7150/ijbs.6.675
4. Nikulina, V.V. Garmanchuk, L.V. Senchylo, N.V. Nikolaenko, T.V. Dzhus, O.I. Ostapchenko, L.I. Khramovska, N.M. Combined influence of teichoic acids from *Staphylococcus aureus* and heterometallic Cu/Cd ethylenediamine complex on peritoneal macrophages and tumor cells *Cytology and Genetics* Volume 48, Issue 6, 3 December 2014, Pages 392–397
5. Viktoriia Nikulina, Liudmyla Garmanchuk, Tetiana Nikolaienko, Natalia Senchylo The Anticancer Effect of Teichoic Acids on Lewis Lung Carcinoma Model // *Journal of Thoracic Oncology*, 2016 Vol. 12 No. 1S, S843–S844
6. Mai, Chun Wai et al. "Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers." *OncoTargets and therapy* 2013; 6: 1573–1587. doi: 10.2147/OTT.S50838
7. de Oliveira J. G., Silva A. E. Polymorphisms of the TLR2 and TLR4 genes are associated with risk of gastric cancer in a Brazilian population. *World Journal of Gastroenterology*. 2012;18(11):1235–1242. doi: 10.3748/wjg.v18.i11.1235.
8. Holohan C., van Schaeybroeck S., Longley D.B., Johnston P.G. (2013) Cancer drug resistance: An evolving paradigm. *Nat. Rev.*, 13, 714–726 doi: 10.1038/nrc3599.
9. G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, and S. Sarkar (2014) Drug Resistance in Cancer: An Overview *Cancers (Basel)*. 6(3): 1769–1792.
10. Chun Lia, Haixia Lib, Kun Jianga, Jing Lia and Xiaodong Gaia TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-1 and IL-10 and tumor cells migration // *Bio-Medical Materials and Engineering* 24 (2014) 869–875

Investigations were supported by grant 10B "The role of metabolic reprogramming of tumor cell sin the development of can cerstem cell phenotype (CSCs): contribution of the adapter protein Ruk / CIN".

Reference (Scopus):

1. Akira, S. and Takeda, K. (2004) Toll-Like Receptor Signaling. *Nature Reviews Immunology*, 4, 499–511. <https://doi.org/10.1038/nri1391>
2. Masahiro Yamamoto and Kiyoshi Takeda, "Current Views of Toll-Like Receptor Signaling Pathways," *Gastroenterology Research and Practice*, vol. 2010, Article ID 240365, 8 pages, 2010. <https://doi.org/10.1155/2010/240365>

Надійшла до редколегії 07.10.19
Отримано виправлений варіант 08.11.19
Підписано до друку 08.11.19

Received in the editorial 07.10.19
Received revised version on 08.11.19
Signed in the press on 08.11.19

Н. Сенчило, канд. біол. наук
Київський національний університет імені Тараса Шевченка, Київ, Україна,
О. Горбач, канд. біол. наук
Національний інститут раку, Київ, Україна,
Л. Дубовцева, студ.
Київський національний університет імені Тараса Шевченка, Київ, Україна,
О. Скачкова, канд. біол. наук
Національний інститут раку, Київ, Україна,
П. Яковлев, канд. мед. наук
Київський національний університет імені Тараса Шевченка, Київ, Україна,
Т. Скатерна, канд. біол. наук
Інститут біохімії ім. О.В. Палладіна НАНУ, Київ, Україна,
Л. Дробот, д-р біол. наук
Інститут біохімії ім. О.В. Палладіна НАНУ, Київ, Україна,
Л. Гарманчук, д-р біол. наук
Київський національний університет імені Тараса Шевченка, Київ, Україна

ТЕЙХОЄВА КИСЛОТА МОДУЮЄ ЕКСПРЕСІЮ ТОЛЛ-ПОДІБНИХ РЕЦЕПТОРІВ 4 У ЧУТЛИВИХ ТА РЕЗИСТЕНТНИХ ДО ДІЇ ЦИСПЛАТИНУ ЛІНІЯХ КЛІТИН ДРІБНОКЛІТИННОГО РАКУ ЛЕГЕНІ

Родина Толл-подібних рецепторів (ТПР) відіграє важливу роль у механізмах розвитку вродженої імунної відповіді, розпізнаючи молекулярні структури патогенних мікроорганізмів. ТПР здатні також відігравати певну роль у розвитку протипухлинної імунної відповіді. Вони можуть або сприяти пухлинному генезу, або пригнічувати його. Окрім того, стимулювання росту пухлинних клітин може бути пов'язане з набуттям лікарської резистентності. Дані про рівень експресії ТПР4 за пухлинного росту є суперечливими. Саме тому мета нашого дослідження полягала у визначенні рівня експресії ТПР4 у клітинах раку легені, чутливих та резистентних до дії цисплатину. Клітинні лінії NCI-H69 та NCI-H69 / CPR (дрібноклітинний рак легені людини) використовували для визначення рівня експресії ТПР4. Інкубацію клітин з тейхоєвою кислотою (1 мкг / мл) проводили в стандартних умовах упродовж двох діб. Рівень експресії ТПР4 у клітинах визначали за допомогою RT-PCR при 7500 ПЛР-системах у реальному часі ("Applied Biosystems", США), специфічних праймерів та асиметричному цiano-катіонному фторохромі SYBRGreen (C32H37N4S+) при λmax = 488 нм флуоресценції при λmax = 522 нм. Було показано, що рівень експресії ТПР4 був майже вдвічі нижчим у клітинах WTH69 порівняно з клітинами H69, резистентними до цисплатину. На відміну від цього, тейхоєва кислота протилежно впливала на рівень експресії ТПР-4. У клітинах WTH69 рівень зріс у 1,3 раза, тоді як у клітинах H69, резистентних до цисплатину, зменшився у 4 рази порівняно з контрольними зразками без додавання тейхоєвої кислоти. Отже, у клітинах раку легені, резистентних до цисплатину з високою експресією ТПР4, можна інгібувати таку, додаючи ліганди до ТПР4.

Ключові слова: експресія ТПР4, лінія клітин резистентна до цисплатину NCI-H69, тейхоєва кислота.

Н. Сенчило, канд. біол. наук
Киевский национальный университет имени Тараса Шевченко, Киев, Украина,

А. Горбач, канд. биол. наук
Национальный институт рака, Киев, Украина,
Л. Дубовцева, студ.
Киевский национальный университет имени Тараса Шевченко, Киев, Украина,
О. Скачкова, канд. биол. наук
Национальный институт рака, Киев, Украина,
П. Яковлев, канд. мед. наук
Киевский национальный университет имени Тараса Шевченко, Киев, Украина,
Т. Скатерна, канд. биол. наук
Институт биохимии им. О.В. Палладина НАНУ, Киев, Украина,
Л. Дробот, д-р биол. наук
Институт биохимии им. О.В. Палладина НАНУ, Киев, Украина,
Л. Гарманчук, д-р биол. наук
Киевский национальный университет имени Тараса Шевченко, Киев, Украина

ТЕЙХОЕВАЯ КИСЛОТА МОДУЛИРУЕТ ЭКСПРЕССИЮ ТОЛЛ-ПОДОБНЫХ РЕЦЕПТОРОВ 4 ЧУВСТВИТЕЛЬНЫХ И РЕЗИСТЕНТНЫХ К ДЕЙСТВИЮ ЦИСПЛАТИНА ЛИНИЙ КЛЕТОК МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО

Семейство Толл-подобных рецепторов (ТПР) играет важную роль в механизмах развития врожденного иммунного ответа, распознавая молекулярные структуры патогенных микроорганизмов. ТПР способны также влиять на развитие противоопухолевого иммунного ответа. Они могут как стимулировать опухолевый рост, так и подавлять его. Стимулирование роста опухолевых клеток может быть связано с приобретением лекарственной резистентности. Данные экспрессии ТПР4 при опухолевом росте противоречивы. Именно поэтому целью исследования являлось определение уровня экспрессии ТПР4 в клетках рака легкого, чувствительных и резистентных к цисплатине. Клетки линий NCI-H69 и NCI-H69 / CPR (мелкоклеточный рак легкого человека) использовали для определения уровня экспрессии ТПР4. Инкубацию клеток с тейхоевой кислотой (1 мкг/мл) проводили в стандартных условиях в течение двух суток. Уровень экспрессии TLR4 в клетках определяли с помощью RT-PCR при 7500 ПЦР-системах в реальном времени ("Applied Bio systems", США), специфических праймеров и асимметрическом циано-катионном фторхроме SYBR Green (C32H37N4S +) при $\lambda_{\text{max}} = 488$ нм флуоресценции при $\lambda_{\text{max}} = 522$ нм. Было показано, что уровень экспрессии ТПР4 был почти в два раза ниже в клетках WT H69 по сравнению с клетками H69, резистентными к цисплатине. В отличие от этого, показано, что тейхоевая кислота имела противоположное влияние на уровень экспрессии ТПР4. В клетках WT H69 уровень экспрессии возрос в 1,3 раза, в клетках H69, резистентных к цисплатине – снизился в 4 раза по сравнению с контрольными образцами без добавления тейхоевой кислоты. Итак, в клетках рака легкого с высокой экспрессией ТПР4, резистентных к цисплатине, можно ингибировать экспрессию, добавляя лиганд к ТПР.

Ключевые слова: экспрессия ТПР4, линия клеток, резистентных к цисплатину NCI-H69, тейхоевая кислота.